Abstract
Butyrylcholinesterase (BuChE) is expressed in brain structures involved in cognition, but the effect of selective BuChE inhibitors on human cognitive function is unknown. We report a patient whose cognitive function deteriorated following a reduction and improved following reinstitution of ethopropazine, a selective BuChE inhibitor. We suggest that, because neurons expressing BuChE may be involved in cognition, there is merit to further evaluation of selective BuChE inhibitors in treating cognitive dysfunction.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Brain / drug effects
-
Brain / physiopathology
-
Butyrylcholinesterase / physiology*
-
Chlorpromazine / adverse effects*
-
Chlorpromazine / therapeutic use
-
Cholinergic Antagonists / adverse effects*
-
Cholinergic Antagonists / therapeutic use
-
Cognition Disorders / chemically induced
-
Cognition Disorders / physiopathology*
-
Dose-Response Relationship, Drug
-
Dyskinesia, Drug-Induced / drug therapy*
-
Humans
-
Male
-
Neurons / drug effects
-
Neurons / physiology
-
Phenothiazines / adverse effects*
-
Phenothiazines / therapeutic use
-
Schizophrenia / drug therapy*
Substances
-
Cholinergic Antagonists
-
Phenothiazines
-
profenamine
-
Butyrylcholinesterase
-
Chlorpromazine